Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04560933 · ClinicalTrials.gov registry record
A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- 186
- Enrollment target
NCT04560933 is a clinical trial that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 186 participants.
The verdict
NCT04560933 has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
Study Summary
To quantify the seroprevalence of antibodies to AAV5, AAV6, and AAV8 and the seroconversion rate over varying follow-up intervals in subjects with hemophilia A
Interventions
- PROCEDURE Blood sample collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2020-08-25 |
| Est. Completion | 2023-10-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04560933
The ClinicalTrials.gov registry entry for NCT04560933 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood sample collection is the first listed.
NCT04560933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04560933 about?
NCT04560933 is a clinical study titled "A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A". To quantify the seroprevalence of antibodies to AAV5, AAV6, and AAV8 and the seroconversion rate over varying follow-up intervals in subjects with hemophilia A
What is the current status of trial NCT04560933?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2020-08-25. Estimated completion is 2023-10-20.
What interventions are being tested in trial NCT04560933?
The interventions under investigation include: Blood sample collection (PROCEDURE).
Who is sponsoring clinical trial NCT04560933?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.